NLS Cyxone

Cyxone, together with its academic partner Medical University of Vienna, has continued to investigate the drug candidate T20K in combination with a kappa opioid receptor agonist. A combination which in pre-clinical experiments demonstrate promising synergistic therapeutic effects and potential disease modifying features in multiple sclerosis. The results build upon previous data which underpin a patent […]

The Phase 2 Covid-19 trial of Rabeximod that has been conducted in Eastern Europe during Q1-Q2 2021 will be closed as the trial has been shown to have a sufficient number of patients enrolled to allow for statistical analysis. Recently Cyxone reported that patient recruitment for the clinical study conducted in Covid-19 patients in Eastern […]

After identifying some valuable new potential treatments for T20K, Cyxone has entered into a research collaboration with Prof. Christian Gruber, the inventor of T20K & Prof Gernot Schabbauer from the Medical University of Vienna. The aim of the study is to deepen the understanding of the mode of action (MoA) of T20K and to explore […]

The company has announced the initiation of key preclinical studies required to enable taking its Multiple Sclerosis drug candidate T20K forward. Firstly, the company will select a Contract Manufacturing Organization (CMO) to establish a new manufacturing process to produce larger quantities of GMP (Good Manufacturing Practice) grade material needed in further preclinical and clinical studies, […]

The company has entered into a collaboration with Professor Costantino Pitzalis, Versus Arthritis Professor of Rheumatology at the William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London. As a world leading expert in pathobiology, translational research and biopsy driven clinical trials, Professor Pitzalis brings invaluable expertise […]